Improved safety and efficacy of ²¹³Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Journal Article · Sun Nov 20 23:00:00 EST 2016 · EJNMMI Research

DOI:https://doi.org/10.1186/s13550-016-0240-5· OSTI ID:1627030

Chan, Ho Sze ^[1]; Konijnenberg, Mark W. ^[2]; Daniels, Tamara ^[3]; Nysus, Monique ^[3]; Makvandi, Mehran ^[3]; de Blois, Erik ^[2]; Breeman, Wouter A. ^[2]; Atcher, Robert W. ^[4]; de Jong, Marion ^[2]; Norenberg, Jeffrey P. ^[3]

---

1. Erasmus MC, Gravendijkwal (Netherlands). Dept. of Radiology and Nuclear Medicine; DOE/OSTI
2. Erasmus MC, Gravendijkwal (Netherlands). Dept. of Radiology and Nuclear Medicine
3. Univ. of New Mexico, Albuquerque, NM (United States). Health Sciences Center. College of Pharmacy. Radiopharmaceutical Sciences Program
4. Univ. of New Mexico, Albuquerque, NM (United States). Health Sciences Center. College of Pharmacy. Radiopharmaceutical Sciences Program; Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

Background: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with ¹⁷⁷Lu-DOTATATE or ⁹⁰Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tubules. Pharmacological protection can reduce renal uptake of radiopeptides, e.g., positively charged amino acids, to saturate in the proximal tubules, thereby enabling higher radioactivity to be safely administered. The aim of this preclinical study was to evaluate the therapeutic effect of ²¹³Bi-DOTATATE with and without renal protection using L-lysine in mice. Tumor uptake and kinetics as a function of injected mass of peptide (range 0.03–3 nmol) were investigated using 111In-DOTATATE. These results allowed estimation of the mean radiation absorbed tumor dose for 213Bi-DOTATATE. Pharmacokinetics and dosimetry of 213Bi-DOTATATE was determined in mice, in combination with renal protection. A dose escalation study with ²¹³Bi-DOTATATE was performed to determine the maximum tolerated dose (MTD) with and without pre-administration of L-lysine as for renal protection. Neutrophil gelatinase-associated lipocalin (NGAL) served as renal biomarker to determine kidney injury. Results: The maximum mean radiation absorbed tumor dose occurred at 0.03 nmol and the minimum at 3 nmol. Similar mean radiation absorbed tumor doses were determined for 0.1 and 0.3 nmol with a mean radiation absorbed dose of approximately 0.5 Gy/MBq ²¹³Bi-DOTATATE. The optimal mass of injected peptide was found to be 0.3 nmol. Tumor uptake was similar for ¹¹¹In-DOTATATE and ²¹³Bi-DOTATATE at 0.3 nmol peptide. Lysine reduced the renal uptake of ²¹³Bi-DOTATATE by 50% with no effect on the tumor uptake. The MTD was <13.0 ± 1.6 MBq in absence of L-lysine and 21.7 ± 1.9 MBq with L-lysine renal protection, both imparting an LD₅₀ mean renal radiation absorbed dose of 20 Gy. A correlation was found between the amount of injected radioactivity and NGAL levels. Conclusions: The therapeutic potential of ²¹³Bi-DOTATATE was illustrated by significantly decreased tumor burden and improved overall survival. Renal protection with L-lysine immediately prior to TAT with ²¹³Bi-DOTATATE prolonged survival providing substantial evidence for pharmacological nephron blockade to mitigate nephrotoxicity.

• Research Organization: Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
• Sponsoring Organization: USDOE Office of Science (SC), Biological and Environmental Research (BER)
• Grant/Contract Number: 89233218CNA000001
• OSTI ID: 1627030
• Journal Information: EJNMMI Research, Journal Name: EJNMMI Research Journal Issue: 1 Vol. 6; ISSN 2191-219X
• Publisher: Springer Open
• Country of Publication: United States
• Language: English

Related Subjects

213Bi-DOTATATE
60 APPLIED LIFE SCIENCES
L-lysine
Maximum tolerated dose
Nephrotoxicity
Radiology
Nuclear Medicine &amp; Medical Imaging
Targeted alpha therapy